Ziqi Xu
First Affiliated Hospital of Zhejiang University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ziqi Xu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:57 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07047014 · Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic StrokeBeijing Tiantan Hospital · recruiting · Stroke, Ischemic, Medium Vessel Occlusions · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:57 UTC. The ranking covers the 200 most relevant of 886 PubMed records, and a shared surname and initials can bring in a namesake. All 886 on PubMed
- Ingenol mebutate gel for actinic keratosis.N Engl J Med · 2012354 citationsRCR 11.7
- 306 citationsRCR 18.8
- 203 citationsRCR 7.1
- 193 citationsRCR 15.2
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.Nat Med · 2025120 citationsRCR 28.6
- Gefapixant in two randomised dose-escalation studies in chronic cough.Eur Respir J · 2020107 citationsRCR 6.8
- Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.Ann Rheum Dis · 2018106 citationsRCR 5.3
- Anthocyanin supplementation improves anti-oxidative and anti-inflammatory capacity in a dose-response manner in subjects with dyslipidemia.Redox Biol · 2020105 citationsRCR 7.4
- Effects of vaginal microbiota transfer on the neurodevelopment and microbiome of cesarean-born infants: A blinded randomized controlled trial.Cell Host Microbe · 2023102 citationsRCR 10.8
- Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.EBioMedicine · 202294 citationsRCR 7.0